Study List:

Study 1:
  NCT Number:                   NCT02327052
  Title:                        Assessment of Speckle Tracking Strain Predictive Value for Myocardial Fibrosis in Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Chagas Disease
  Interventions:                Other: No intervention was performed.
  Outcome Measures:             Correlation Between Longitudinal Global Strain and the Percentage of Myocardial Fibrosis on Magnetic Resonance
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   58
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Other|Time Perspective: Cross-Sectional
  Other IDs:                    PCL01-04
  Start Date:                   January 2011
  Primary Completion Date:      December 2013
  Completion Date:              December 2013
  First Posted:                 December 30, 2014
  Results First Posted:         March 24, 2021
  Last Update Posted:           March 24, 2021
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02327052

Study 2:
  NCT Number:                   NCT01842880
  Title:                        MicroRNAs as Biomarkers in Patients With Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                
  Outcome Measures:             Correlation of plasmatic levels of MicroRNAs with the percentage of heart fibrosis|Correlation of plasmatic levels of MicroRNAs with the functional cardiovascular capacity|Correlation of plasmatic levels of MicroRNAs with the left ventricular function|Correlation of plasmatic levels of MicroRNAs with the serum levels of Pro-BNP.|Correlation of plasmatic levels of MicroRNAs with the serum levels of TNF-alpha|Correlation of plasmatic levels of MicroRNAs with the serum levels of IFN-gamma.
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Cross-Sectional
  Other IDs:                    CEP-41-10-2
  Start Date:                   January 2011
  Primary Completion Date:      June 2013
  Completion Date:              December 2013
  First Posted:                 April 30, 2013
  Results First Posted:         
  Last Update Posted:           February 20, 2015
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01842880

Study 3:
  NCT Number:                   NCT01842854
  Title:                        Galectin-3 as a Biomarker in Patients With Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                
  Outcome Measures:             Correlation of plasmatic levels of Galectin-3 with the percentage of heart fibrosis|Correlation of plasmatic levels of Galectin-3 with the functional capacity of the heart|Correlation of plasmatic levels of Galectin-3 with the serum levels of Pro-BNP.|Correlation of plasmatic levels of Galectin-3 with the serum levels of TNF-alpha|Correlation of plasmatic levels of Galectin-3 with the serum levels of IFN-gamma.
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Cross-Sectional
  Other IDs:                    CEP-41-10|Galectin-Chagas
  Start Date:                   January 2011
  Primary Completion Date:      June 2015
  Completion Date:              June 2015
  First Posted:                 April 30, 2013
  Results First Posted:         
  Last Update Posted:           November 28, 2017
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01842854

Study 4:
  NCT Number:                   NCT01842867
  Title:                        Syndecan-4 as a Biomarker in Patients With Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                
  Outcome Measures:             Correlation of plasmatic levels of syndecan-4 with the percentage of heart fibrosis|Correlation of plasmatic levels of syndecan-4 with the functional cardiovascular capacity|Correlation of plasmatic levels of Syndecan-4 with the left ventricular function|Correlation of plasmatic levels of Syndecan-4 with the serum levels of Pro-BNP.|Correlation of plasmatic levels of Syndecan-4 with the serum levels of TNF-alpha|Correlation of plasmatic levels of Syndecan-4 with the serum levels of IFN-gamma.
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Cross-Sectional
  Other IDs:                    CEP-41-10-1
  Start Date:                   January 2011
  Primary Completion Date:      June 2015
  Completion Date:              June 2015
  First Posted:                 April 30, 2013
  Results First Posted:         
  Last Update Posted:           October 12, 2015
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01842867

Study 5:
  NCT Number:                   NCT04274101
  Title:                        Nifurtimox Versus Benznidazole Effectiveness and Tolerance for Chagas Disease Treatment
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Other: Clinical Manifestations|Diagnostic Test: Serologic response|Diagnostic Test: Direct method|Behavioral: Adverse events
  Outcome Measures:             Nifurtimox versus Benznidazole serologic, parasitemia and clinical response for treatment in patients|Nifurtimox versus Benznidazole security and tolerance|To compare Chagas disease characteristics associated with treatment
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires
  Gender:                       All
  Age:                          up to 18 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   900
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    Nifurtimox vs. Benznidazole
  Start Date:                   June 1, 2018
  Primary Completion Date:      August 1, 2020
  Completion Date:              February 1, 2021
  First Posted:                 February 18, 2020
  Results First Posted:         
  Last Update Posted:           April 30, 2020
  Locations:                    Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04274101

Study 6:
  NCT Number:                   NCT04984616
  Title:                        Atorvastatin on Inflammation and Cardiac Function in Chronic Chagas Disease
  Acronym:                      ATOCHA
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chronic Chagas Disease
  Interventions:                Drug: 40 mg Atorvastatin/day for 120 days P.O.|Drug: Atorvastatin 80|Drug: Placebo
  Outcome Measures:             Number of patients that present a change in the phase of the chronic cardiomyopathy|plasma levels of cytokines (pg/mL)|Plasma levels of endothelial adhesion molecules (pg/mL)|Proportion of patients with change in heart rate measured by electrocardiographic examination|Proportion of patients with changes in the QT interval duration (milliseconds)|Proportion of patients with abnormalities in ventricular electrical conduction determined by the duration of the QRS interval (milliseconds)|Proportion of patients with alterations in ventricular function as measured by changes in the ejection fraction percentage estimated by echocardiography|Plasma levels of Cardiac function biomarkers (pg/mL)|Parasite load in a blood sample (number of parasites/mL)|Incidence of severe adverse events
  Sponsor/Collaborators:        Juan D. Maya|University of Chile
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   300
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    U1111-1267-3513
  Start Date:                   October 12, 2021
  Primary Completion Date:      December 2024
  Completion Date:              January 2025
  First Posted:                 July 30, 2021
  Results First Posted:         
  Last Update Posted:           November 16, 2021
  Locations:                    Hospital Felix Bulnes, Quinta Normal, Región Metropolitana, Chile|Hospital San Juan de Dios, Santiago, Región Metropolitana, Chile|Hospital San Martin, Quillota, Valparaiso, Chile|Hospital Gustavo Fricke, Viña del Mar, Valparaíso, Chile
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04984616

Study 7:
  NCT Number:                   NCT01678599
  Title:                        Optimization of PCR Technique to Assess Parasitological Response for Patients With Chronic Chagas Disease
  Acronym:                      PCR
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole
  Outcome Measures:             The primary endpoints are: - A positive or negative PCR at baseline (BL) among serology positive patients.|- Identification of the optimal relationship between sensitivity and feasibility at baseline.|- Identification of the optimal relationship between sensitivity and Identification of the optimal relationship between sensitivity and feasibility at End Of Treatment (EOT)|- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at EOT - to be estimated using 1) the current sampling schedule (CS), the most sensitive one and the optimal one.|- The proportion of patients who convert from PCR (+) at baseline to PCR (-) at 6 and 12 months follow-up - to be estimated using 1) the current sampling schedule (CS) and the optimal one (based on EOT data).|- Relative reduction [(parasite count at baseline - parasite count at EOT, 6 and 12 months)/parasite count at baseline] of parasitemia - to be evaluated through parasite load at EOT, 6 and 12 months through quantitative PCR.
  Sponsor/Collaborators:        Drugs for Neglected Diseases|Medecins Sans Frontieres, Netherlands
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 4
  Enrollment:                   220
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Diagnostic
  Other IDs:                    MSF/DNDi-CD-PCR-01
  Start Date:                   April 2011
  Primary Completion Date:      December 2012
  Completion Date:              April 2013
  First Posted:                 September 5, 2012
  Results First Posted:         
  Last Update Posted:           June 25, 2018
  Locations:                    Medicin Sans Frontièrs (MSF), Aiquile, Bolivia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01678599

Study 8:
  NCT Number:                   NCT04024163
  Title:                        Prospective Study of Benznidazole for Chagas' Disease Children With Chronic Indeterminate Chagas Disease
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole
  Outcome Measures:             Serological Cure by Conventional ELISA|Serological Cure by Conventional ELISA at different timepoints|Serological Cure by two conventional serology tests at 72 month|Serological Cure by two conventional serology tests at 48 months|Serological Cure by three serology tests at different timepoints|Serological Cure by Non-Conventional ELISA at different timepoints|Cure by qPCR at different timepoints|Serological titres reduction at different timepoints|Progression of clinical disease at different timepoints|Progression of clinical disease and serological cure by one assay at different timepoints|Progression of clinical disease and serological cure by two assays at different timepoints
  Sponsor/Collaborators:        Insud Pharma|Chemo Research S.L.
  Gender:                       All
  Age:                          2 Years to 18 Years   (Child, Adult)
  Phases:                       Phase 3
  Enrollment:                   164
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    LPRI747-301
  Start Date:                   September 19, 2019
  Primary Completion Date:      August 30, 2026
  Completion Date:              March 2, 2027
  First Posted:                 July 18, 2019
  Results First Posted:         
  Last Update Posted:           July 31, 2020
  Locations:                    Hospital de Ninos "Dr. Ricardo Gutierrez", Ciudad Autónoma de Buenos Aires, Argentina|Hospital "Luis Carlos Lagomaggiore", Mendoza, Argentina|Hospital Pediatrico "Dr. Humberto Notti", Mendoza, Argentina|Hospital Público Descentralizado Dr. Guillermo Rawson, San Juan, Argentina|Centro de Enfermedad de Chagas y Patologías Regionales, Santiago Del Estero, Argentina|Antigua Hospital Viedma, Cochabamba, Bolivia|Fundación Salud para el Trópico, Santa Marta, Colombia|Centro de Atención e Investigación Médica (CAIMED), Yopal, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04024163

Study 9:
  NCT Number:                   NCT02386358
  Title:                        Etiologic Treatment With Benznidazole in Adult Patients With Chronic Chagas Disease. A Randomized Clinical Trial
  Acronym:                      TRAENA
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: Placebo
  Outcome Measures:             Cardiovascular Mortality|Development of heart failure|Severe arrhythmias with hemodynamic compromise or pacemaker implant or Implantable cardiac defibrillator|Electrocardiographic endpoints. New development of permanent changes in the electrocardiographic|Changes in clinical stage in chronic Chagas disease|Enlargement of the left ventricle (LV) detected by echocardiography.|New Heart Failure|Stroke|Serological negativization|Development and validation of RT-PCR|Changes of the secondary objectives during RCT development. New single endpoints|Combined clinical endpoints:
  Sponsor/Collaborators:        Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben|National Council of Scientific and Technical Research, Argentina|Pan American Health Organization|Becas Carrillo Oñativia, Ministerio de Salud, Argentina|Drugs for Neglected Diseases
  Gender:                       All
  Age:                          20 Years to 55 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   910
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    TRAENA
  Start Date:                   March 1999
  Primary Completion Date:      December 2012
  Completion Date:              April 2013
  First Posted:                 March 11, 2015
  Results First Posted:         
  Last Update Posted:           March 11, 2015
  Locations:                    Instituto Nacional de Parasitología Dr Mario Fatala Chaben, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02386358

Study 10:
  NCT Number:                   NCT03784391
  Title:                        Study on Benefits of Therapy With Nifurtimox in Chagas Disease, a Parasitic Illness Mostly Transmitted to Humans by a Bug, Using Information From Patient Medical Records in Argentina
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas' Disease
  Interventions:                Drug: Lampit (Nifurtimox, BAYA2502)
  Outcome Measures:             Parasitological cure of adult patients with chronic Chagas' disease|Parasitological cure of pediatric patients with acute and chronic Chagas' disease|Occurrence of cardiac manifestations in patients with chronic Chagas' disease|Treatment of Cardiomyopathy and/or Heart Failure
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          0 Years and older   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   3000
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Retrospective
  Other IDs:                    20302
  Start Date:                   December 14, 2018
  Primary Completion Date:      April 6, 2020
  Completion Date:              April 6, 2020
  First Posted:                 December 21, 2018
  Results First Posted:         
  Last Update Posted:           April 8, 2021
  Locations:                    Many locations, Multiple Locations, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03784391

Study 11:
  NCT Number:                   NCT01489228
  Title:                        Proof-of-Concept Study of E1224 to Treat Adult Patients With Chagas Disease
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chronic Chagas Disease, Indeterminate
  Interventions:                Drug: E1224|Drug: Benznidazole|Drug: Placebo
  Outcome Measures:             Serial negative qualitative Polymerase Chain Reaction (PCR) results (3 negative PCR results from 3 samples to be collected over 7 days) as a measure of parasitological cure at end of treatment|Consistently negative serial qualitative PCR as a measure of sustained parasitological eradication|Qualitative PCR as a measure of parasite eradication|Quantitative PCR as a measure of change in parasite load over time|Incidence of serological conversion to negative and changes in titers over time as measured by conventional and non-conventional serologies|Changes in the levels of biomarkers over time: brain natriuretic peptide, troponin T, selected prothrombotic factors, lytic antibodies, apolipoprotein A1 and multiplex serodiagnostic assay|Area under the plasma concentration versus time curve (AUC), Peak Plasma Concentration (Cmax), Minimum Plasma Concentration (Cmin), Clearance, Volume of Distribution , and Plasma Terminal Half-Life (t1/2) of ravuconazole and benznidazole|Incidence and severity of adverse events (clinical and laboratory)|Incidence of Serious Adverse Events and/or adverse events leading to treatment discontinuation|Early and late predictors of sustainable response to treatments|Correlation of pharmacokinetic parameters with parasitological response, changes in biomarkers and safety outcomes
  Sponsor/Collaborators:        Drugs for Neglected Diseases|Eisai Co., Ltd.
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   230
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    DNDi-CH-E1224-001
  Start Date:                   June 2011
  Primary Completion Date:      August 2012
  Completion Date:              December 2013
  First Posted:                 December 9, 2011
  Results First Posted:         
  Last Update Posted:           December 21, 2011
  Locations:                    Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas, Cochabamba, Bolivia|Plataforma de Atención Integral a los Pacientes con Enfermidad de Chagas, Tarija, Bolivia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01489228

Study 12:
  NCT Number:                   NCT02625974
  Title:                        Prospective Study of a Pediatric Nifurtimox Formulation for Chagas' Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox (Lampit, BAYA2502)|Drug: Placebo
  Outcome Measures:             Percentage of Participants Cured|Incidence Rate of Seronegative Conversion for Subjects Received at Least One Dose of the 60-day Nifurtimox Treatment Regimen.(Part 2)|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 1|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 3|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 6|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 8|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 9|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 10|Number of Subjects With Clinical Signs/ Symptoms of Chagas Disease at Visit 11|Number of Subjects With Positive Results in Concentration Test for T. Cruzi (for Subjects <8 Months of Age)|Number of Subjects With a Positive Serological Response Using Non-conventional Enzyme-linked Immunosorbent Assay-F29 (ELISAF29) Test|Number of Subjects With Positive Quantitative Polymerase Chain Reaction (qPCR) Results|Number of Subjects With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs)|Number of Subjects With Treatment-emergent High Blood Chemistry Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Blood Chemistry Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent High Hematology Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Hematology Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent High Coagulation Abnormalities by Treatment (Part 1)|Number of Subjects With Treatment-emergent Low Coagulation Abnormalities by Treatment (Part 1)|Number of Subjects With Abnormal Urinalysis Findings Considered as Clinically Significant or Reported as Adverse Events (AEs)|Number of Subjects With Abnormal ECG Findings Considered as Clinically Significant by Investigators (Part 1)|Mean Changes in Vital Signs (Systolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Diastolic Blood Pressure) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Respiratory Rate) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs (Heart Rate) Between the Treatment Groups From Baseline (Part 1)|Mean Changes in Vital Signs(Temperature) Between the Treatment Groups From Baseline (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 2 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 3 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 6 (Part 1)|Nifurtimox Concentration Over Time in Plasma at Visit 8 (Part 1)|Incidence of Seronegative Conversion Received at Least One Dose of the 30-day Nifurtimox Treatment Regimen. (Part 2)|Proportion of Responders With Seronegative Conversion and no Evidence of Cardiomyopathy (Part 2)|Antibody Titer in Plasma Over Time in All Subjects (Part 2)
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          up to 17 Years   (Child)
  Phases:                       Phase 3
  Enrollment:                   330
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    16027
  Start Date:                   January 27, 2016
  Primary Completion Date:      July 25, 2018
  Completion Date:              August 10, 2021
  First Posted:                 December 9, 2015
  Results First Posted:         October 29, 2019
  Last Update Posted:           September 22, 2021
  Locations:                    La Plata, Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina|San Salvador de Jujuy, Jujuy, Argentina|Posadas, Misiones, Argentina|Rosario, Santa Fe, Argentina|Corrientes, Argentina|Formosa, Argentina|La Rioja, Argentina|Mendoza, Argentina|Mendoza, Argentina|Salta, Argentina|Salta, Argentina|San Juan, Argentina|Santiago del Estero, Argentina|Tucuman, Argentina|Cochabamba, Bolivia|Punata, Bolivia|Tarija, Bolivia|Barranquilla, Atlántico, Colombia|Yopal, Casanare, Colombia|Santa Marta, Magdalena, Colombia|Floridablanca, Santander, Colombia
  Study Documents:              "Study Protocol", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/Prot_001.pdf|"Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/74/NCT02625974/SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT02625974

Study 13:
  NCT Number:                   NCT03587766
  Title:                        Oral Fexinidazole Dosing Regimens for the Treatment of Adults With Chronic Indeterminate Chagas Disease
  Acronym:                      FEXI12
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas' Disease (Chronic) Nos
  Interventions:                Drug: Fexinidazole|Drug: Placebo Oral Tablet
  Outcome Measures:             Incidence and severity of adverse events.|Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine AUC0-t values, for all dose levels.|Pharmacokinetic : measure of blood concentration of fexinidazole, fexinidazole sulfoxide and fexinidazole sulfone in order to determine Cmax values, for all dose levels.
  Sponsor/Collaborators:        Drugs for Neglected Diseases
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   45
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    DNDi-FEX-12-CH|2016-004905-15
  Start Date:                   November 13, 2017
  Primary Completion Date:      December 19, 2018
  Completion Date:              August 28, 2019
  First Posted:                 July 16, 2018
  Results First Posted:         
  Last Update Posted:           September 23, 2020
  Locations:                    Hospital Clinic, Barcelona, Catalunia, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03587766

Study 14:
  NCT Number:                   NCT01755377
  Title:                        New Tools for the Diagnosis, Prognosis and Treatment Follow-up in Chagas Disease
  Acronym:                      BIOMARCHA
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole
  Outcome Measures:             Biomarkers for prognosis, early diagnosis and effectiveness of treatment.|Cardiac function after antiparasitic treatment
  Sponsor/Collaborators:        Barcelona Centre for International Health Research
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       
  Enrollment:                   63
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    BIOMARCHA
  Start Date:                   December 2012
  Primary Completion Date:      May 2016
  Completion Date:              June 2016
  First Posted:                 December 24, 2012
  Results First Posted:         
  Last Update Posted:           August 22, 2016
  Locations:                    International Health Department, Hospital Clinic, Barcelona, Barcelona, Cataluña, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01755377

Study 15:
  NCT Number:                   NCT03189056
  Title:                        Lower Urinary Tract Dysfunction in Chronic Chagas' Disease : Clinical and Urodynamic Presentation
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas' Disease (Chronic) With Other Organ Involvement
  Interventions:                Diagnostic Test: Chagas serology|Biological: Creatinina|Procedure: Urodynamic exploration
  Outcome Measures:             Symptomatic patients|Megabladder|Mega ureter|Hyperactive bladder|Detrusor underactivity|Renal insufficiency|Urinary recurrent infections|Urinary sphincter insufficiency|Erectile dysfunction in males|Hypofertility
  Sponsor/Collaborators:        Institut de Recherche pour le Developpement|Instituto de Investigación Hospital Universitario La Paz
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       
  Enrollment:                   152
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Ecologic or Community|Time Perspective: Prospective
  Other IDs:                    Chagas_urology
  Start Date:                   July 14, 2017
  Primary Completion Date:      October 20, 2017
  Completion Date:              October 20, 2017
  First Posted:                 June 16, 2017
  Results First Posted:         
  Last Update Posted:           March 29, 2018
  Locations:                    SELADIS Institute, Universidad Mayor de San Andrès, La Paz, Bolivia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03189056

Study 16:
  NCT Number:                   NCT01755403
  Title:                        Population Pharmacokinetics in Benznidazole-treated Adults With Chronic With Chagas Disease
  Acronym:                      CINEBENZ
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole
  Outcome Measures:             Population pharmacokinetic parameters of Benznidazole|Adverse reactions
  Sponsor/Collaborators:        Barcelona Centre for International Health Research
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 4
  Enrollment:                   52
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CINEBENZ
  Start Date:                   December 2012
  Primary Completion Date:      November 2013
  Completion Date:              November 2013
  First Posted:                 December 24, 2012
  Results First Posted:         
  Last Update Posted:           May 27, 2015
  Locations:                    International Health Department, Hospital Clinic, Barcelona, Barcelona, Cataluña, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01755403

Study 17:
  NCT Number:                   NCT00699387
  Title:                        Population Pharmacokinetics of Benznidazole in Children With Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole
  Outcome Measures:             Description of Population pharmacokinetics parameters of benznidazole (i.e. median population clearance, absorption and volume of distribution, and their respective inter-individual variabilities)|Adverse events
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires|Thrasher Research Fund|The Hospital for Sick Children|Fundacion Bunge y Born (Argentina)|Universidad Nacional de La Plata|Consejo de Investigacion en Salud Gobierno de Buenos Aires
  Gender:                       All
  Age:                          2 Years to 12 Years   (Child)
  Phases:                       Not Applicable
  Enrollment:                   37
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Basic Science
  Other IDs:                    CHAGAS-CHILDREN-POPPK
  Start Date:                   April 2007
  Primary Completion Date:      May 2011
  Completion Date:              May 2011
  First Posted:                 June 18, 2008
  Results First Posted:         
  Last Update Posted:           August 1, 2011
  Locations:                    Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00699387

Study 18:
  NCT Number:                   NCT01377480
  Title:                        A Study of the Use of Oral Posaconazole (POS) in the Treatment of Asymptomatic Chronic Chagas Disease (P05267)
  Acronym:                      STOP CHAGAS
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Chagas Disease
  Interventions:                Drug: Posaconazole|Drug: Placebo for posaconazole|Drug: Benznidazole
  Outcome Measures:             Percentage of Participants With a Successful Response as Measured by Qualitative Polymerase Chain Reaction
  Sponsor/Collaborators:        Merck Sharp & Dohme LLC
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   120
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    P05267|MK-5592-055
  Start Date:                   July 6, 2011
  Primary Completion Date:      July 22, 2014
  Completion Date:              January 12, 2015
  First Posted:                 June 21, 2011
  Results First Posted:         August 10, 2015
  Last Update Posted:           August 27, 2018
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01377480

Study 19:
  NCT Number:                   NCT01162967
  Title:                        Clinical Trial For The Treatment Of Chronic Chagas Disease With Posaconazole And Benznidazole
  Acronym:                      CHAGASAZOL
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: Posaconazole
  Outcome Measures:             Parasitological cure measured by a real time PCR in blood sample|Parasitological cure measured by real time PCR in blood sample|Safety and tolerability of both drugs
  Sponsor/Collaborators:        Hospital Universitari Vall d'Hebron Research Institute|Hospital Vall d'Hebron|Tropical Medicine and International Health Unit Drassanes. Barcelona|International Health Unit Metropolitana Nord. Santa Coloma.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   78
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CHAGASAZOL01
  Start Date:                   September 2010
  Primary Completion Date:      December 2012
  Completion Date:              March 2013
  First Posted:                 July 15, 2010
  Results First Posted:         
  Last Update Posted:           September 10, 2013
  Locations:                    International Health Unit Metropolitana Nord, Santa Coloma, Barcelona, Spain|Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain|International Health Unit Drassanes, Barcelona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01162967

Study 20:
  NCT Number:                   NCT00453700
  Title:                        Prevalence of Chagas Disease in Immigrant Patients With Conduction Abnormalities on Electrocardiogram
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Procedure: Trypanosoma cruzi serology
  Outcome Measures:             Prevalence of positive trypanosoma cruzi serologies
  Sponsor/Collaborators:        Olive View-UCLA Education & Research Institute|Centers for Disease Control and Prevention
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       
  Enrollment:                   327
  Funded Bys:                   Other|U.S. Fed
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    06H-561004
  Start Date:                   January 2007
  Primary Completion Date:      April 2009
  Completion Date:              December 2010
  First Posted:                 March 29, 2007
  Results First Posted:         
  Last Update Posted:           March 13, 2019
  Locations:                    OV-UCLA Medical Center, Sylmar, California, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00453700

Study 21:
  NCT Number:                   NCT04897516
  Title:                        New Scheme for Treatment With Benznidazole
  Acronym:                      NuestroBen
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Short regimen of benznidazole|Drug: Standard treatment with benznidazole
  Outcome Measures:             Proportion of patients with sustained negativation of parasitemia according to the results of qualitative PCR tests|Proportion of patients with negative parasitemia at 6 and 12 months follow-up form the beginning of treatment|Incidence and severity of adverse events|Incidence of SAEs, Adverse Events of Special Interest (AESIs) and/or adverse events that cause treatment interruption.
  Sponsor/Collaborators:        Laboratorio Elea Phoenix S.A.|Drugs for Neglected Diseases initiative
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Phase 3
  Enrollment:                   362
  Funded Bys:                   Industry|Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    NuestroBen
  Start Date:                   July 28, 2021
  Primary Completion Date:      February 2023
  Completion Date:              February 2023
  First Posted:                 May 21, 2021
  Results First Posted:         
  Last Update Posted:           September 17, 2021
  Locations:                    Instituto Nacional de Parasitología "Dr. Mario Fatala Chaben", Buenos Aires, Argentina|Fundación Huésped, Buenos Aires, Argentina|Hospital Francisco Javier Muñiz, Buenos Aires, Argentina|Hospital Donación Francisco Santojanni, Buenos Aires, Argentina|Instituto de Cardiología de Corrientes "Juana Francisca Cabral", Corrientes, Argentina|Centro de Chagas y Patología Regional, Hospital Independencia, Santiago Del Estero, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04897516

Study 22:
  NCT Number:                   NCT03191162
  Title:                        Evaluation of Different Benznidazole Regimens for the Treatment of Chronic Chagas Disease.
  Acronym:                      MULTIBENZ
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Trypanosoma Cruzi Infection
  Interventions:                Drug: Benznidazole
  Outcome Measures:             Proportion of patients with negative parasitaemia measured by PCR during the first 12 months after starting treatment
  Sponsor/Collaborators:        Hospital Universitari Vall d'Hebron Research Institute
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   240
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    2016-003789-21
  Start Date:                   April 21, 2017
  Primary Completion Date:      April 2018
  Completion Date:              September 2018
  First Posted:                 June 19, 2017
  Results First Posted:         
  Last Update Posted:           June 19, 2017
  Locations:                    Instituto Nacional de Parasitología Dr. Mario Fatala Chaben (ANLIS), Buenos Aires, Argentina|Instituto de Cardiología de Corrientes Juana Francisca Cabral, Corrientes, Argentina|Centro de Pesquisas René Rachou - Fundação Oswaldo Cruz. (FIOCRUZ), Belo Horizonte, Brazil|Hospital Universitário Clemente de Faria, Montes Claros, Brazil|Fundación Cardioinfantil - Instituto de Cardiología, Bogotá, Colombia|Centro Atencion y Diagnóstico de Enfermedades Infecciosas, Bucaramanga, Colombia|Infectious Disease Department Vall d'Hebron Hospital, Barcelona, Spain
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03191162

Study 23:
  NCT Number:                   NCT01650792
  Title:                        Clinical Assessment, Neuroimaging and Immunomarkers in Chagas Disease Study (CLINICS)
  Acronym:                      CLINICS
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease With Heart Failure
  Interventions:                Drug: Aspirin
  Outcome Measures:             Brain magnetic resonance imaging lesions|Biomarkers|Proportion of high intensity transient signals on transcranial Doppler monitorization
  Sponsor/Collaborators:        Federal University of Bahia|National Institutes of Health (NIH)|National Institute of Neurological Disorders and Stroke (NINDS)
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   500
  Funded Bys:                   Other|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    R01NS064905
  Start Date:                   July 2012
  Primary Completion Date:      June 2022
  Completion Date:              June 2022
  First Posted:                 July 26, 2012
  Results First Posted:         
  Last Update Posted:           August 20, 2021
  Locations:                    Hospital Universitario Professor Edgard Santos, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01650792

Study 24:
  NCT Number:                   NCT01744405
  Title:                        Study Of Nifurtimox Transfer Into Breastmilk In Lactating Women With Chagas Disease
  Acronym:                      LACTNFX
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Lactation
  Interventions:                
  Outcome Measures:             Nifurtimox concentration in breastmilk and in plasma|Incidence of adverse drug reactions in women treated with nifurtimox during lactation
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires
  Gender:                       Female
  Age:                          18 Years to 40 Years   (Adult)
  Phases:                       
  Enrollment:                   12
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    LACT-NIFURTIMOX
  Start Date:                   December 2012
  Primary Completion Date:      December 2013
  Completion Date:              March 2015
  First Posted:                 December 6, 2012
  Results First Posted:         
  Last Update Posted:           March 18, 2015
  Locations:                    Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01744405

Study 25:
  NCT Number:                   NCT01547533
  Title:                        Study of Benznidazole Transfer Into Breastmilk in Lactating Women With Chagas Disease
  Acronym:                      LACTBENZ
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Lactation
  Interventions:                
  Outcome Measures:             Benznidazole concentration in breastmilk and in plasma|incidence of adverse drug reactions in women treated with benznidazole during lactation
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires
  Gender:                       Female
  Age:                          18 Years to 40 Years   (Adult)
  Phases:                       
  Enrollment:                   10
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    LACT-BENZNIDAZOLE
  Start Date:                   August 2011
  Primary Completion Date:      June 2013
  Completion Date:              December 2013
  First Posted:                 March 8, 2012
  Results First Posted:         
  Last Update Posted:           March 18, 2015
  Locations:                    Parasitology and Chagas Service, Buenos Aires Children´s Hospital Ricardo Gutierrez, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01547533

Study 26:
  NCT Number:                   NCT01539161
  Title:                        Reveal Chagas: Clinical Evidence of the Implantable Cardiac Monitor in Patients With Chagas Disease
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Heart Diseases
  Interventions:                Device: Implantable Cardiac Monitor|Procedure: Standard of Care
  Outcome Measures:             To compare the time to the physician's decision to treat for electrical disorders (brady/tachyarrhythmias) between the two randomized groups.|Summarize the recorded arrhythmic events stored within the ICM (bradyarrhythmia and tachyarrhythmia.|Compute the time duration spent in arrhythmias for ICM patients.|Compute the incidence of symptomatic arrhythmias in patients with an ICM|Compare the time to the physician's decision to treat with components of the composite primary endpoint between randomization arms.|Compare the mortality rate between randomization arms.
  Sponsor/Collaborators:        Medtronic Cardiac Rhythm and Heart Failure
  Gender:                       All
  Age:                          21 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   12
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    Reveal Chagas
  Start Date:                   July 2013
  Primary Completion Date:      April 2015
  Completion Date:              April 2015
  First Posted:                 February 27, 2012
  Results First Posted:         
  Last Update Posted:           October 12, 2016
  Locations:                    Hospital General de Agudos "Juan Fernandez", Buenos Aires, Caba, Argentina|Hospital Interzonal General de Agudos "General José de San Martin", La Plata, Argentina|Fundacion Cardioinfantil, Bogota, Colombia|Hospital Militar Central, Bogota, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01539161

Study 27:
  NCT Number:                   NCT04090489
  Title:                        Congenital Chagas Disease: Long Term Follow up of Treated Children. Preliminary Report or Cardiological Evaluation in Chagas Disease Treated Children
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Chagas Cardiomyopathy
  Interventions:                
  Outcome Measures:             To evaluate the efficacy of CD treatment in preventing the development of cardiac alterations in treated children.|Post treatment evaluation of treatment response biomarkers
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires
  Gender:                       All
  Age:                          6 Years to 50 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   120
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    Holter Chagas Children
  Start Date:                   January 22, 2015
  Primary Completion Date:      November 1, 2019
  Completion Date:              March 1, 2020
  First Posted:                 September 16, 2019
  Results First Posted:         
  Last Update Posted:           April 24, 2020
  Locations:                    Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04090489

Study 28:
  NCT Number:                   NCT03378661
  Title:                        BENDITA BEnznidazole New Doses Improved Treatment and Associations
  Acronym:                      BENDITA
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: E1224|Drug: E1224 Placebo|Drug: Benznidazole Placebo
  Outcome Measures:             Parasitological response as determined by serial negative qualitative PCR results (3 negative PCR results, from 3 samples to be collected in the same day) at EOT and sustained parasitological clearance until 6 months follow-up.|Incidence of Adverse Events (AEs)|Severity of Adverse Events (AEs)|Incidence of Serious Adverse Events (SAEs) and/or adverse events leading to treatment discontinuation|Sustained parasitological clearance at 12 weeks and 12 months of follow-up|Parasite clearance as measured by qualitative PCR|Change in parasite load over time assessed as measured by quantitative PCR|Serological response by conventional serology assessed at 12 months of follow up and non-conventional serology assessed at W12, 4, 6, and 12 months of follow up. (changes in titters over time)
  Sponsor/Collaborators:        Drugs for Neglected Diseases
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   210
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    DNDi-CH-E1224-003
  Start Date:                   November 30, 2016
  Primary Completion Date:      January 28, 2018
  Completion Date:              July 27, 2018
  First Posted:                 December 20, 2017
  Results First Posted:         
  Last Update Posted:           December 20, 2017
  Locations:                    Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas., Sucre, Chuquisaca, Bolivia|Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas., Cochabamba, Bolivia|Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas., Tarija, Bolivia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03378661

Study 29:
  NCT Number:                   NCT04084379
  Title:                        Implementation Strategy of Bio-molecular Techniques for Early Diagnose of Congenital Syphilis and Chagas Diseases
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Syphilis
  Interventions:                
  Outcome Measures:             Implementation of Bio-molecular Techniques (PCR) for Early Diagnose of Congenital Syphilis and Chagas Diseases|Implementation of Bio-molecular Techniques (PCR) as terapeutic response biomarker for Congenital Syphilis and Chagas Disease|Identification of different genotypes of T.pallidum in samples to create a database of T.pallidum genotypes
  Sponsor/Collaborators:        Hospital de Niños R. Gutierrez de Buenos Aires
  Gender:                       All
  Age:                          1 Day to 18 Years   (Child, Adult)
  Phases:                       
  Enrollment:                   560
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    ETMIplus ChC/SiC
  Start Date:                   July 1, 2019
  Primary Completion Date:      July 30, 2021
  Completion Date:              September 1, 2022
  First Posted:                 September 10, 2019
  Results First Posted:         
  Last Update Posted:           November 12, 2019
  Locations:                    Parasitology Division, Children's Hospital "R Gutierrez" of Buenos Aires, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04084379

Study 30:
  NCT Number:                   NCT03334838
  Title:                        Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients - Dietary Habits Study
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas' Disease
  Interventions:                Drug: Nifurtimox (Lampit, BAYA2502)
  Outcome Measures:             AUC(0-tlast) of nifurtimox (evaluation of food effect)|Cmax of nifurtimox (evaluation of food effect)|Number of participants with treatment-emergent adverse events (TEAEs)|AUC(0-tlast)/D of nifurtimox (evaluation of food effect)|Cmax/D of nifurtimox (evaluation of food effect)
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   36
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16006
  Start Date:                   June 10, 2019
  Primary Completion Date:      November 7, 2019
  Completion Date:              January 29, 2020
  First Posted:                 November 7, 2017
  Results First Posted:         
  Last Update Posted:           December 30, 2020
  Locations:                    FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03334838

Study 31:
  NCT Number:                   NCT03350295
  Title:                        Study Will Evaluate the Relative Bioavailability, Safety, and Tolerability of Single Doses of Nifurtimox 30 mg Tablets Exhibiting Different in Vitro Dissolution Characteristics, and to Evaluate the Relative Bioavailability of Nifurtimox 30 mg and 120 mg
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox (Lampit, BAYA2502)
  Outcome Measures:             AUC(0-tlast) of nifurtimox|Cmax of nifurtimox|AUC of nifurtimox|Number of participants with adverse events|AUC divided by dose: AUC/D|AUC(0-tlast) divided by dose: AUC(0-tlast)/D|Cmax divided by dose: Cmax/D
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   48
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16007
  Start Date:                   June 14, 2018
  Primary Completion Date:      September 18, 2018
  Completion Date:              December 14, 2018
  First Posted:                 November 22, 2017
  Results First Posted:         
  Last Update Posted:           December 12, 2019
  Locations:                    FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03350295

Study 32:
  NCT Number:                   NCT02606864
  Title:                        Study to Assess the Food Effect on the Pharmacokinetics of Nifurtimox Tablets in Chronic Chagas' Patients
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox (BAYa2502)
  Outcome Measures:             Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point[AUC(0-tlast)]|Plasma concentration nifurtimox characterized by Cmax|Plasma concentration of nifurtimox characterized by tmax|Plasma concentration of nifurtimox characterized by AUC|Number of participants with adverse events as a measure of safety and tolerability
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   36
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16005
  Start Date:                   December 2015
  Primary Completion Date:      April 2016
  Completion Date:              August 2016
  First Posted:                 November 17, 2015
  Results First Posted:         
  Last Update Posted:           November 15, 2016
  Locations:                    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02606864

Study 33:
  NCT Number:                   NCT00875173
  Title:                        Selenium Treatment and Chagasic Cardiopathy (STCC)
  Acronym:                      STCC
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Selenium|Drug: Placebo (for Selenium)
  Outcome Measures:             Ejection fraction by echocardiography|Electrocardiography
  Sponsor/Collaborators:        Oswaldo Cruz Foundation|Conselho Nacional de Desenvolvimento Científico e Tecnológico|Ministry of Health, Brazil
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   130
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    Oswaldo Cruz
  Start Date:                   October 2008
  Primary Completion Date:      December 2016
  Completion Date:              December 2020
  First Posted:                 April 3, 2009
  Results First Posted:         
  Last Update Posted:           November 10, 2015
  Locations:                    Instituto Nacional de Infectologia/Instituto de Pesquisa Clínica Evandro Chagas, Rio de Janeiro, RJ, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00875173

Study 34:
  NCT Number:                   NCT01927224
  Title:                        Study to Assess Bioequivalence of 30 and 120 mg Nifurtimox Tablets in Chronic Chagas' Patients
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox (BAYa2502) (4 x 30 mg tablet)|Drug: Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|Drug: Nifurtimox (BAYa2502) (120 mg tablet)
  Outcome Measures:             Area under the drug-concentration vs. time curve of nifurtimox from time 0 to the last data point [AUC(0-tn)]|Maximum drug concentration of nifurtimox in plasma (Cmax)|Number of participants with adverse events as a measure of safety and tolerability
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   37
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    16004
  Start Date:                   November 2013
  Primary Completion Date:      May 2014
  Completion Date:              September 2014
  First Posted:                 August 22, 2013
  Results First Posted:         
  Last Update Posted:           October 16, 2015
  Locations:                    Buenos Aires, Ciudad Auton. de Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01927224

Study 35:
  NCT Number:                   NCT02369978
  Title:                        CHICAMOCHA 3 - Equivalence of Usual Interventions for Trypanosomiasis (EQUITY)
  Acronym:                      CHICAMOCHA-3
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox|Drug: Benznidazole|Drug: Placebo
  Outcome Measures:             Quantitative Polymerase Chain Reaction (qPCR) for Trypanosoma cruzi|T. cruzi positive serology status|Mean change in T. cruzi antibody titers
  Sponsor/Collaborators:        Universidad Autónoma de Bucaramanga|Fundación Cardioinfantil Instituto de Cardiología|Instituto Nacional de Salud, Colombia|Instituto Nacional de Parasitologia Dr. Mario Fatala Chaben
  Gender:                       All
  Age:                          20 Years to 55 Years   (Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   500
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    124156935014
  Start Date:                   August 2015
  Primary Completion Date:      August 2018
  Completion Date:              February 2019
  First Posted:                 February 24, 2015
  Results First Posted:         
  Last Update Posted:           July 21, 2017
  Locations:                    Fundación Oftalmológica de Santander - Clínica Ardila Lulle (FOSCAL), Bucaramanga, Santander, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02369978

Study 36:
  NCT Number:                   NCT02498782
  Title:                        Study to Evaluate Fexinidazole Dosing Regimens for the Treatment of Adult Patients With Chagas Disease
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Trypanosomiasis, South American|South American Trypanosomiasis|Disease, Chagas
  Interventions:                Drug: Fexinidazole|Drug: Placebo
  Outcome Measures:             Parasitological cure rate (PCR)|Adverse events|Serious Adverse events|Parasite Clearance (qualitative PCR)|Parasite load|Serological response|Blood culture for parasite genotyping
  Sponsor/Collaborators:        Drugs for Neglected Diseases
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   140
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    DNDi-CH-FEXI-001
  Start Date:                   July 2014
  Primary Completion Date:      September 2015
  Completion Date:              February 2016
  First Posted:                 July 15, 2015
  Results First Posted:         
  Last Update Posted:           July 15, 2015
  Locations:                    Plataforma Atención Integral de Pacientes con Enfermedad de Chagas, Cochabamba, Bolivia|Plataforma de Atención Integral de Pacientes con Enfermedad de Chagas, Tarija, Bolivia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02498782

Study 37:
  NCT Number:                   NCT03981523
  Title:                        New Therapies and Biomarkers for Chagas Infection
  Acronym:                      TESEO
  Status:                       Active, not recruiting
  Study Results:                No Results Available
  Conditions:                   Trypanosoma Cruzi Infection|Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: Nifurtimox
  Outcome Measures:             Sustained Parasitological Clearance by qPCR at End of Follow-Up (36 months)|Changes Over Time in the blood parasitic load by qPCR|Changes Over Time in the Conventional Serology using parasite antigenic mixture|Changes Over Time in the Conventional Serology using recombinant parasite antigens|Changes Over Time in the Non-Conventional Serology Biomarker "Lytic Anti-α-Gal Antibodies"|Changes Over Time in the Non-Conventional Serology Biomarker "Anti-KMP11 Antibodies"|Changes in the Non-Conventional Serology Biomarker "Anti-HSP70 Antibodies"|Changes Over Time in the Non-Conventional Serology Biomarker "Anti-PFR2 Antibodies"|Changes Over Time in the Non-Conventional Serology Biomarker "Anti-Peptide 3973 Antibodies"|Changes Over Time in the Non-Conventional Serology Biomarker "Trypomastigote Excreted/Secreted Antigens (TESA)"
  Sponsor/Collaborators:        University of Texas, El Paso|Fundación Ciencia y Estudios Aplicados para el Desarrollo en Salud y Medio Ambiente (CEADES)|Barcelona Institute for Global Health|Institute of Parasitology and Biomedicine Lopez Neyra|U.S. Food and Drug Administration (FDA)|Drugs for Neglected Diseases|Mundo Sano Foundation|National Institute of Allergy and Infectious Diseases (NIAID)
  Gender:                       All
  Age:                          18 Years to 50 Years   (Adult)
  Phases:                       Phase 2
  Enrollment:                   450
  Funded Bys:                   Other|NIH
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    743474|U01AI129783
  Start Date:                   December 18, 2019
  Primary Completion Date:      May 31, 2024
  Completion Date:              July 31, 2024
  First Posted:                 June 11, 2019
  Results First Posted:         
  Last Update Posted:           November 7, 2022
  Locations:                    Platform for the Comprehensive Care of Patients with Chagas Disease, Cochabamba, Cercado, Bolivia|Platform for the Comprehensive Care of Patients with Chagas Disease, Tarija, Cercado, Bolivia|Platform for the Comprehensive Care of Patients with Chagas Disease, Sucre, Bolivia
  Study Documents:              "Informed Consent Form", https://ClinicalTrials.gov/ProvidedDocs/23/NCT03981523/ICF_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03981523

Study 38:
  NCT Number:                   NCT03704181
  Title:                        Colchicine for Patients With Chagas´ Disease( B1 Stage)
  Acronym:                      COACH
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Colchicine Resistance
  Interventions:                Drug: Colchicine 0.5 MG twice day for one year|Drug: Placebo Oral Tablet
  Outcome Measures:             Effect of colchicine on myocardial inflammation assessed by magnetic resonance imaging|Effect of colchicine on myocardial fibrosis assessed by magnetic resonance imaging|Effect of colchicine on inflammatory markers such as interleukin-1, interleukin-6, interleukin-8, interleukin-10|Effect of colchicine on inflammatory marker such as TNF-α|Effect of colchicine on inflammatory marker such as interferon-gama|Effect of colchicine on T Cruzi polymerase chain reaction
  Sponsor/Collaborators:        University of Sao Paulo General Hospital|Fundação de Amparo à Pesquisa do Estado de São Paulo
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   60
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment
  Other IDs:                    4436/16/102
  Start Date:                   October 1, 2018
  Primary Completion Date:      December 30, 2020
  Completion Date:              January 5, 2021
  First Posted:                 October 12, 2018
  Results First Posted:         
  Last Update Posted:           March 11, 2019
  Locations:                    Fabio Fernandes, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03704181

Study 39:
  NCT Number:                   NCT04984265
  Title:                        SBRT in Chagas Disease Ventricular Tachycardia
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Ventricular Tachycardia|Chagas Disease|Cardiac Arrhythmia
  Interventions:                Radiation: Stereotactic Body Radiation Therapy
  Outcome Measures:             Safety of SBRT for the treatment of Ventricular Tachycardia|Efficacy of SBRT for the treatment of Ventricular Tachycardia|Time to VT Recurrence|VT Burden|Mortality|Cardiac Mortality
  Sponsor/Collaborators:        University of Sao Paulo General Hospital
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 1|Phase 2
  Enrollment:                   10
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    4920/19/139
  Start Date:                   July 14, 2021
  Primary Completion Date:      July 31, 2022
  Completion Date:              July 31, 2023
  First Posted:                 July 30, 2021
  Results First Posted:         
  Last Update Posted:           July 30, 2021
  Locations:                    University of Sao Paulo General Hospital, Sao Paulo, SP, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04984265

Study 40:
  NCT Number:                   NCT02295215
  Title:                        Exercise Training in Patients With Chagasic Heart Disease Without Ventricular Dysfunction
  Acronym:                      CH0660/10
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Other: Exercise
  Outcome Measures:             Sympathetic nerve activityAutonomic control|Peak oxygen consumption|Skeletal muscle strength
  Sponsor/Collaborators:        University of Sao Paulo General Hospital
  Gender:                       All
  Age:                          25 Years to 60 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   24
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    
  Start Date:                   June 2013
  Primary Completion Date:      December 2015
  Completion Date:              December 2015
  First Posted:                 November 20, 2014
  Results First Posted:         
  Last Update Posted:           November 20, 2014
  Locations:                    Heart Institute - HC-FMUSP, Sao Paulo, SP, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02295215

Study 41:
  NCT Number:                   NCT01549236
  Title:                        Population Pharmacokinetics Study of Benznidazole in Children With Chagas'Disease
  Acronym:                      Pop PK Chagas
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas' Disease
  Interventions:                Drug: Benznidazole 12,5mg or 100mg
  Outcome Measures:             Pharmacokinetics Endpoints|Efficacy Endpoints|Safety endpoints|Safety Endpoints
  Sponsor/Collaborators:        Drugs for Neglected Diseases|LAT Research
  Gender:                       All
  Age:                          1 Day to 12 Years   (Child)
  Phases:                       Phase 4
  Enrollment:                   80
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    DNDi-CD-PEDBZ-001
  Start Date:                   May 2011
  Primary Completion Date:      August 2012
  Completion Date:              October 2012
  First Posted:                 March 9, 2012
  Results First Posted:         
  Last Update Posted:           June 25, 2018
  Locations:                    Hospital General de Niños Ricardo Gutierrez, Buenos Aires, Argentina|Hospital de Niños "Doctor Héctor Quintana", Jujuy, Argentina|Hospital Público Materno Infantil, Salta, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01549236

Study 42:
  NCT Number:                   NCT01787968
  Title:                        Congenital Transmission of Lineages I and II of Trypanosoma Cruzi
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                
  Outcome Measures:             Congenital transmission of Trypanosoma cruzi|Birth outcomes
  Sponsor/Collaborators:        Tulane University School of Public Health and Tropical Medicine|Institute for Clinical Effectiveness and Health Policy|Laboratory of Parasitology Universite Libre de Bruxelles|Instituto de Enfermedades Infecciosas y Parasitol Antonio Vidal|Lab de Parasitologia Universidad Autonoma de Yucatan|Tulane University
  Gender:                       Female
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   28348
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    R01AI083563
  Start Date:                   April 2011
  Primary Completion Date:      December 2013
  Completion Date:              December 2013
  First Posted:                 February 11, 2013
  Results First Posted:         
  Last Update Posted:           November 16, 2016
  Locations:                    Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States|Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina|Laboratory of Parasitology, Universite Libre de Bruxelles, Brussels, Belgium|Inst. de Enfermedades Infecciosas y Parasitol Antonio Vidal, Tegucigalpa, Honduras|Lab. de Parasitologia, Universidad Autonoma de Yucatan, Merida, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01787968

Study 43:
  NCT Number:                   NCT03892213
  Title:                        Pharmacokinetic Drug-Drug Interaction Study
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: E1224
  Outcome Measures:             Maximum serum concentration (Cmax) of Benznidazole|Time of occurrence of maximum plasma concentration (tmax) of Benznidazole|Area under the serum concentration versus time curve from time zero to the time (t) corresponding to the last quantifiable concentration (AUC 0-t) of Benznidazole|Area under the concentration-time curve from time zero to infinity with extrapolation of the terminal phase (AUC 0-∞) of Benznidazole|Terminal half-life (t1/2) of Benznidazole|Maximum serum concentration (Cmax) of Ravuconazole.|Time of occurrence of maximum plasma concentration (tmax) of Ravuconazole.|The area under the blood drug concentration vs. time curve from time zero (pre-dose) to 24 h post-dose (AUC 0-24)|Incidence of Adverse Events (AEs)|Clinically significant alterations in pulse rate|Clinically significant alterations in blood pressure|Clinically significant alterations in 12-lead ECG|Clinically significant Haematology abnormalities (hemoglobin, RBC, hematocrit, MCV, MCH, MCHC, WBC, including differential, platelet counts)|Clinically significant Biochemistry abnormalities (albumin (ALB), ALP, ALT, AST, gamma-glutamyl transferase (GGT), chlorides (Cl-), creatinine, glucose (GLU), potassium (K+), sodium (Na+), total bilirubin (TBIL), total proteins (TP), Urea.|Clinically significant Urinalysis abnormalities (leukocytes, pH, proteins, urobilinogen, blood, nitrites, glucose, ketone bodies, bilirubin).
  Sponsor/Collaborators:        Drugs for Neglected Diseases|PhinC Development
  Gender:                       Male
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   28
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    DNDi-CH-E1224-002
  Start Date:                   October 2014
  Primary Completion Date:      December 2014
  Completion Date:              January 2015
  First Posted:                 March 27, 2019
  Results First Posted:         
  Last Update Posted:           March 27, 2019
  Locations:                    FP Clinical Pharma - Juncal 4484 - 3o piso, Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03892213

Study 44:
  NCT Number:                   NCT01662362
  Title:                        Abbott ESA Chagas Assay Post-Market Study
  Acronym:                      ESA
  Status:                       Completed
  Study Results:                Has Results
  Conditions:                   Chagas Disease
  Interventions:                Device: Testing Donor Specimens with ESA Chagas
  Outcome Measures:             ESA Chagas Testing of US Blood Donor Specimens Repeatedly Reactive by ABBOTT PRISM Chagas|ESA Testing of Preselected Donor Specimens Nonreactive by ABBOTT PRISM Chagas
  Sponsor/Collaborators:        Abbott Diagnostics Division
  Gender:                       All
  Age:                          17 Years and older   (Child, Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   63
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)
  Other IDs:                    7B5-02-10P02-01
  Start Date:                   July 2012
  Primary Completion Date:      December 2012
  Completion Date:              December 2012
  First Posted:                 August 10, 2012
  Results First Posted:         February 20, 2014
  Last Update Posted:           February 20, 2014
  Locations:                    LifeSource, Rosemont, Illinois, United States|American Red Cross, Gaithersburg, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01662362

Study 45:
  NCT Number:                   NCT05477953
  Title:                        An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About the Risk of Pregnancy Complications and About the Mother's and Baby's Health
  Acronym:                      
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Nifurtimox (BAYA2502)
  Outcome Measures:             Major Congenital Malformations (birth defects)|Events of Interest in Neonates and Infants through 12 Months of Age: Hospitalizations for serious illness|Events of Interest in Neonates and Infants through 12 Months of Age: Medications|Events of Interest in Neonates and Infants through 12 Months of Age: Growth and development milestones|Events of Interest in Neonates and Infants through 12 Months of Age: Neonatal or infant mortality|Maternal Complications: Premature rupture of membranes (PROM)|Maternal Complications: Preeclampsia|Maternal Complications: Severe pregnancy-induced hypertension (PIH)|Maternal Complications: Proteinuria|Maternal Complications: Gestational diabetes|Maternal Complications: Measures of fetal growth deficiency (small for gestational age)|Spontaneous abortion|Elective/Induced abortion|Fetal death/Still birth|Preterm delivery|Live Birth|Ectopic or Molar Pregnancy
  Sponsor/Collaborators:        Bayer
  Gender:                       Female
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   50
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    21944
  Start Date:                   August 17, 2022
  Primary Completion Date:      March 31, 2032
  Completion Date:              March 31, 2032
  First Posted:                 July 28, 2022
  Results First Posted:         
  Last Update Posted:           December 15, 2022
  Locations:                    UBC Pregnancy Coordinating Center, Morgantown, West Virginia, United States|Many Locations, Multiple Locations, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05477953

Study 46:
  NCT Number:                   NCT03672487
  Title:                        Short-course Benznidazole Treatment to Reduce Trypanosoma Cruzi Parasitic Load in Women of Reproductive Age
  Acronym:                      BETTY
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Drug: Benznidazole|Drug: Placebo Oral Tablet
  Outcome Measures:             Frequency of positive PCR and the parasitic load measured by qPCR immediately after BZN 30d/150mg|The frequency of positive PCR and the parasitic load measured by qPCR 10 months after BZN 30d/150mg|The frequency of serious adverse events leading to treatment interruption of BZN 30d/150mg compared to 60d/300mg immediately after BZN 30d/150mg
  Sponsor/Collaborators:        Tulane University School of Public Health and Tropical Medicine|Institute for Clinical Effectiveness and Health Policy|University of California, San Diego|Tulane University
  Gender:                       Female
  Age:                          13 Years and older   (Child, Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   600
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    R01HD095587
  Start Date:                   June 1, 2019
  Primary Completion Date:      May 31, 2023
  Completion Date:              May 31, 2023
  First Posted:                 September 14, 2018
  Results First Posted:         
  Last Update Posted:           January 18, 2023
  Locations:                    University of California at San Diego, San Diego, California, United States|Tulane School of Public Health and Tropical Medicine, New Orleans, Louisiana, United States|Institute for Clinical Effectiveness and Health Policy, Buenos Aires, Argentina
  Study Documents:              "Study Protocol and Statistical Analysis Plan", https://ClinicalTrials.gov/ProvidedDocs/87/NCT03672487/Prot_SAP_000.pdf
  URL:                          https://ClinicalTrials.gov/show/NCT03672487

Study 47:
  NCT Number:                   NCT02346123
  Title:                        Determination of Genetic Polymorphisms in Chronic Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                Genetic: Gathering of samples of genetic material
  Outcome Measures:             Presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in the different forms of Chagas disease|Presence of polymorphisms of the genes CLDN-1, LGALS3, SOCS3, IL-28B, CCL5 in subjects with and without myocardial fibrosis
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   55
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Time Perspective: Cross-Sectional
  Other IDs:                    CEP-41-11
  Start Date:                   June 2015
  Primary Completion Date:      June 2015
  Completion Date:              June 2015
  First Posted:                 January 26, 2015
  Results First Posted:         
  Last Update Posted:           October 12, 2015
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02346123

Study 48:
  NCT Number:                   NCT02646943
  Title:                        Longitudinal Study of Patients With Chronic Chagas Cardiomyopathy in Brazil (SaMi_Trop Project)
  Acronym:                      SaMi-Trop
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease
  Interventions:                
  Outcome Measures:             Death|Changes in the ECG pattern|Hospitalization due to cardiovascular
  Sponsor/Collaborators:        University of Sao Paulo|National Institute of Allergy and Infectious Diseases (NIAID)|Federal University of Minas Gerais|Federal University of São João del-Rei
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   1959
  Funded Bys:                   Other|NIH
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    2111129|P50AI098461-02
  Start Date:                   July 2013
  Primary Completion Date:      July 2014
  Completion Date:              August 2014
  First Posted:                 January 6, 2016
  Results First Posted:         
  Last Update Posted:           January 6, 2016
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02646943

Study 49:
  NCT Number:                   NCT02099903
  Title:                        Renal Denervation in Patients With Heart Failure Secondary to Chagas Disease
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Heart Failure|Heart Failure, Systolic|Chagas Disease|Chagas Cardiomyopathy
  Interventions:                Device: transcatheter renal denervation
  Outcome Measures:             Composite: death, myocardial infarction, cerebrovascular event, need of intervention on renal arteries and renal function impairment (decrease in estimated GFR > 30% from baseline).|Left Ventricular Ejection Fraction (LVEF) by echocardiography.|New York Heart Association (NYHA) functional class.|6-minute walk test|Peak Oxygen consumption (VO2) by ergoespirometry.
  Sponsor/Collaborators:        InCor Heart Institute|Johnson & Johnson
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    18400613.1.0000.0068
  Start Date:                   March 2014
  Primary Completion Date:      December 2014
  Completion Date:              August 2015
  First Posted:                 March 31, 2014
  Results First Posted:         
  Last Update Posted:           March 31, 2014
  Locations:                    Heart Institute - InCor. University of Sao Paulo Medical School, Sao Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02099903

Study 50:
  NCT Number:                   NCT00123916
  Title:                        BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas' Disease
  Acronym:                      BENEFIT
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Trypanosomiasis|Heart Disease
  Interventions:                Drug: Benznidazole|Drug: Placebo
  Outcome Measures:             Composite of First of cardiovascular events: Death, Resuscitated Cardiac Arrest, Sustained VentricularTachycardia, New/worsening Heart Failure, New Pacemaker/ICD, Stroke/TIA or other Embolic Events, Cardiac Transplant.|New development of any of the following echo changes, segmental wall motion abnormalities, ventricular aneurysm, reduction in LV ejection fraction >5%, increase in LVDD> 5 mm compared to baseline.|New 12 lead ECG alterations (complete bundle branch block, fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc).|Progression of NYHA functional class by at least one category|New 12 lead electrocardiogram (ECG) alterations (complete bundle branch block; fascicular block, advanced atrio-ventricular block, atrial fibrillation, etc.)|Progression of New York Heart Association (NYHA) functional class by at least one category|Evaluation of safety (adverse events: dermatitis, peripheral neuropathy, gastro-intestinal intolerance, leucopenia [2500 x 10^9 L]), tolerance and adherence to treatment|Determination of the efficacy of benznidazole in patients with Chronic Chagas heart disease based on a 50% reduction in both qualitative and quantitative PCR.|Safety and tolerability of benznidazole
  Sponsor/Collaborators:        Population Health Research Institute|Canadian Institutes of Health Research (CIHR)|World Health Organization|Instituto Dante Pazzanese de Cardiologia|University of Sao Paulo
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   2854
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    BEN01|CONEP-11394
  Start Date:                   November 2004
  Primary Completion Date:      July 2015
  Completion Date:              August 2015
  First Posted:                 July 26, 2005
  Results First Posted:         
  Last Update Posted:           March 3, 2020
  Locations:                    BENEFIT Ivestigational Site, Ciudad Autónoma de Buenos Aires, Apital Federal, Argentina|BENEFIT Investigational Site, Belén De Escobar, Buenos Aires, Argentina|BENEFIT Investigational Site, Isidro Casanova, Buenos Aires, Argentina|BENEFIT Investigational Site, San Juan, Buenos Aires, Argentina|BENEFIT Investigational Site, Santiago del Estero, Buenos Aires, Argentina|BENEFIT Investigational Site, Santiago del Estero, Buenos Aires, Argentina|BENEFIT Investigational Site, Ciudad Autónoma de Buenos Aires, Capital Federal, Argentina|BENEFIT Investigational Site, San Fernando del Valle de Catamarca, Catamarca, Argentina|BENEFIT Investigational Site, Charata, Chaco, Argentina|BENEFIT Investigational Site, Paraná, Entre Rios, Argentina|BENEFIT Investigational Site, Buenos Aires, General Rodríguez Partido, Argentina|BENEFIT Investigational Site, San Salvador de Jujuy, Jujuy, Argentina|BENEFIT Investigational Site, Corrientes, Rosario, Santa Fe, Argentina|BENEFIT Investigational Site, Rosario, Santa Fe, Argentina|BENEFIT Investigational Site, Añatuya, Santiago Del Estero, Argentina|BENEFIT Investigational Site, Santiago Del Estero, Sgo. Del Estero, Argentina|BENEFIT Investigational Site, Buenos Aires, Argentina|BENEFIT Investigational Site, Salta, Argentina|BENEFIT Investigational Site, Tupiza, Potosi, Bolivia|BENEFIT Investigational Site, Salvador, Bahaia, Brazil|BENEFIT Investigational Site, Salvador, Bahaia, Brazil|BENEFIT Investigational Site, Salvador, Bahaia, Brazil|BENEFIT Investigational Site, Carmo, Belo Horizonte, Brazil|BENEFIT Investigational Site, Brasília, Brazilian Federal District, Brazil|BENEFIT Investigational Site, Goiânia, GO, Brazil|BENEFIT Investigational Site, Goiânia, GO, Brazil|BENEFIT Investigational Site, Goiânia, GO, Brazil|BENEFIT Investigational Site, Uberlandia, MG, Brazil|BENEFIT Investigational Site, Uberlândia, MG, Brazil|BENEFIT Investigational Site, Uberaba, Minas Gerais, Brazil|BENEFIT Investigational Site, Curitiba, Parana, Brazil|BENEFIT Investigational Site, Recife, Pernambuco, Brazil|BENEFIT Investigational Site, Pelotas, Rio Grande Do Sul, Brazil|BENEFIT Investigational Site, Campinas, São Paulo, Brazil|BENEFIT Investigational Site, Ribeirão Preto, São Paulo, Brazil|BENEFIT Investigational Site, São José do Rio Preto, São Paulo, Brazil|BENEFIT Investigational Site, São José do Rio Preto, São Paulo, Brazil|BENEFIT Investigational Site, Votuporanga, São Paulo, Brazil|BENEFIT Investigational Site, Rio de Janeiro, Brazil|BENEFIT Investigational Site, Rio de Janeiro, Brazil|BENEFIT Investigational Site, São Paulo, Brazil|BENEFIT Investigational Site, São Paulo, Brazil|BENEFIT Investigational Site, São Paulo, Brazil|BENEFIT Investigational Site, São Paulo, Brazil|BENEFIT Investigational Site, Bogota, Bogotá, Colombia|BENEFIT Investigational Site, San Gil, Santander, Colombia|BENEFIT Ivestigational Site, San Salvador, El Salvador
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00123916

Study 51:
  NCT Number:                   NCT01874795
  Title:                        Effect of Ganglionar Electrical Stimulation on Central Arterial Pressure
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Heart Failure|Chagas Disease
  Interventions:                Device: TENS|Device: Placebo
  Outcome Measures:             tonometry|Cardiorespiratory Evaluation
  Sponsor/Collaborators:        University of Brasilia
  Gender:                       All
  Age:                          40 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   30
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Supportive Care
  Other IDs:                    071/2011
  Start Date:                   March 2012
  Primary Completion Date:      May 2012
  Completion Date:              June 2012
  First Posted:                 June 11, 2013
  Results First Posted:         
  Last Update Posted:           June 11, 2013
  Locations:                    University of Brasilia, Brasilia, DF, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01874795

Study 52:
  NCT Number:                   NCT04023227
  Title:                        Efficacy and Safety of Sacubitril/Valsartan Compared With Enalapril on Morbidity, Mortality, and NT-proBNP Change in Patients With CCC
  Acronym:                      PARACHUTE-HF
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Heart Failure
  Interventions:                Drug: Sacubitril/valsartan|Drug: Enalapril
  Outcome Measures:             Hierarchical composite endpoint composed of time to CV death, time to first HF hospitalization, relative change in NT-proBNP from baseline to Week 12|Time to the first occurrence of a composite of CV events|Time to all-cause mortality|Time to sudden death or resuscitated sudden cardiac arrest|Number of visits to an ER due to HF (where intravenous therapy is required)|Number of days alive out of the hospital|Number of ventricular fibrillation or sustained ventricular tachycardia|Number of anti-tachycardia pacing or shock therapies
  Sponsor/Collaborators:        Novartis Pharmaceuticals|Novartis
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   900
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CLCZ696B3302
  Start Date:                   December 10, 2019
  Primary Completion Date:      September 16, 2024
  Completion Date:              September 16, 2024
  First Posted:                 July 17, 2019
  Results First Posted:         
  Last Update Posted:           January 13, 2023
  Locations:                    Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Caba, Buenos Aires, Argentina|Novartis Investigative Site, Ramos Mejia, Buenos Aires, Argentina|Novartis Investigative Site, San Martin, Buenos Aires, Argentina|Novartis Investigative Site, Temperley, Buenos Aires, Argentina|Novartis Investigative Site, Villa Maria, Cordoba, Argentina|Novartis Investigative Site, Ciudad de Salta, Provincia De Salta, Argentina|Novartis Investigative Site, Tucuman, San Miguel De Tucuman, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, Rosario, Santa Fe, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, San Miguel de Tucuman, Tucuman, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Buenos Aires, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Cordoba, Argentina|Novartis Investigative Site, Corrientes, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Formosa, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Mendoza, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santa Fe, Argentina|Novartis Investigative Site, Santiago del Estero, Argentina|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Salvador, BA, Brazil|Novartis Investigative Site, Fortaleza, CE, Brazil|Novartis Investigative Site, Brasila/DF, DF, Brazil|Novartis Investigative Site, Brasilia, DF, Brazil|Novartis Investigative Site, Brasília, Distrito Federal, Brazil|Novartis Investigative Site, Goiania, Goiás, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Goiania, GO, Brazil|Novartis Investigative Site, Sao Luis, MA, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Belo Horizonte, MG, Brazil|Novartis Investigative Site, Uberaba, MG, Brazil|Novartis Investigative Site, Uberlândia, MG, Brazil|Novartis Investigative Site, Belo Horizonte, Minas Gerais, Brazil|Novartis Investigative Site, Montes Claros, Minas Gerais, Brazil|Novartis Investigative Site, Passos, Minas Gerais, Brazil|Novartis Investigative Site, Uberlandia, Minas Gerais, Brazil|Novartis Investigative Site, Belem, PA, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Recife, PE, Brazil|Novartis Investigative Site, Teresina, Piaui, Brazil|Novartis Investigative Site, Londrina, PR, Brazil|Novartis Investigative Site, Natal, Rio Grande Do Norte, Brazil|Novartis Investigative Site, Rio de Janeiro, RJ, Brazil|Novartis Investigative Site, Botucatu, Sao Paulo, Brazil|Novartis Investigative Site, Braganca Paulista, Sao Paulo, Brazil|Novartis Investigative Site, Ribeirao Preto, Sao Paulo, Brazil|Novartis Investigative Site, Santo Andre, Sao Paulo, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, Sao Paulo, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, Sao Paulo, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Campinas, SP, Brazil|Novartis Investigative Site, Indaiatuba, SP, Brazil|Novartis Investigative Site, Marilia, SP, Brazil|Novartis Investigative Site, Sao Jose do Rio Preto, SP, Brazil|Novartis Investigative Site, Sao Paulo, SP, Brazil|Novartis Investigative Site, São Paulo, SP, Brazil|Novartis Investigative Site, Tatuí, SP, Brazil|Novartis Investigative Site, Votuporanga, SP, Brazil|Novartis Investigative Site, Sao Paulo, Brazil|Novartis Investigative Site, Bogota, Cundinamarca, Colombia|Novartis Investigative Site, Santa Marta, Magdalena, Colombia|Novartis Investigative Site, San Gil, Santander, Colombia|Novartis Investigative Site, Bogota DC, Colombia|Novartis Investigative Site, Florida Blanca, Colombia|Novartis Investigative Site, Floridablanca, Colombia|Novartis Investigative Site, Ciudad de Mexico, Cdmx, Mexico|Novartis Investigative Site, Ciudad de Mexico, Gustavo A Madero, Mexico|Novartis Investigative Site, Pachuca, Hidalgo, Mexico|Novartis Investigative Site, Guadalajara, Jalisco, Mexico|Novartis Investigative Site, Merida, Yucatan, Mexico|Novartis Investigative Site, Oaxaca, Mexico|Novartis Investigative Site, Xalapa, Mexico
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04023227

Study 53:
  NCT Number:                   NCT00005455
  Title:                        Chagas Disease as an Undiagnosed Type of Cardiomyopathy in the United States
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Heart Diseases|Myocardial Diseases|Chagas Disease
  Interventions:                
  Outcome Measures:             
  Sponsor/Collaborators:        National Heart, Lung, and Blood Institute (NHLBI)
  Gender:                       Male
  Age:                          up to 100 Years   (Child, Adult, Older Adult)
  Phases:                       
  Enrollment:                   
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                
  Other IDs:                    4488|Z01HL005264
  Start Date:                   January 1993
  Primary Completion Date:      
  Completion Date:              December 1993
  First Posted:                 May 26, 2000
  Results First Posted:         
  Last Update Posted:           July 15, 2016
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00005455

Study 54:
  NCT Number:                   NCT04239144
  Title:                        Sympathetic Denervation by Video-assisted Thoracoscopy in Control of Cardiac Arrhythmias in Patients With Chagas Disease
  Acronym:                      
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Ventricular Arrythmia
  Interventions:                Procedure: Left trunk sympathectomy|Procedure: Catheter ablation
  Outcome Measures:             Ventricular Tachycardia Recurrence Following sympathectomy|Ventricular Tachycardia Recurrence Following sympathectomy - Burden|Ventricular Tachycardia Recurrence Following sympathectomy compared to catheter ablation.|Ventricular Ectopy Density|Length of Hospital Stay|Rate of complications following intervention|Impact of treatment on left ventricular function - 6 months|Impact of treatment on left ventricular function - 12 months|Mortality
  Sponsor/Collaborators:        University of Sao Paulo General Hospital|Biosense Webster, Inc.
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   30
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    49701215.2.0000.0068
  Start Date:                   November 9, 2018
  Primary Completion Date:      December 9, 2020
  Completion Date:              December 9, 2021
  First Posted:                 January 23, 2020
  Results First Posted:         
  Last Update Posted:           January 23, 2020
  Locations:                    Heart Institute of Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04239144

Study 55:
  NCT Number:                   NCT03524768
  Title:                        Microvascular Endothelial Function in a Cohort of Patients With the Cardiac Form of Chronic Chagas Disease.
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy
  Interventions:                Diagnostic Test: skin laser speckle contrast imaging and video-capillaroscopy
  Outcome Measures:             Endothelium-dependent skin microvascular function|Endothelium-dependent skin capillary density
  Sponsor/Collaborators:        National Institute of Cardiology, Laranjeiras, Brazil
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   70
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    CHAGASKASALTIBIRIÇÁ
  Start Date:                   August 20, 2018
  Primary Completion Date:      August 1, 2020
  Completion Date:              August 1, 2020
  First Posted:                 May 15, 2018
  Results First Posted:         
  Last Update Posted:           August 20, 2020
  Locations:                    National Institute of Cardiology, Ministry of Health, Brazil, Rio de Janeiro, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03524768

Study 56:
  NCT Number:                   NCT00511589
  Title:                        Chagas Disease Diagnostic - Inconclusive Serology
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Parasitemia|Protozoan Infections
  Interventions:                Other: chagas disease diagnostic
  Outcome Measures:             
  Sponsor/Collaborators:        UPECLIN HC FM Botucatu Unesp
  Gender:                       All
  Age:                          18 Years to 60 Years   (Adult)
  Phases:                       Not Applicable
  Enrollment:                   
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Intervention Model: Parallel Assignment|Masking: None (Open Label)
  Other IDs:                    upeclin/HC/FMB-Unesp-pre01
  Start Date:                   
  Primary Completion Date:      
  Completion Date:              
  First Posted:                 August 6, 2007
  Results First Posted:         
  Last Update Posted:           March 24, 2011
  Locations:                    Univerdidade Estadual Paulista, Botucatu, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00511589

Study 57:
  NCT Number:                   NCT02517632
  Title:                        Physical Exercise Program in Chronic Chagas Heart Disease
  Acronym:                      PEACH
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Chagas Cardiomyopathy
  Interventions:                Behavioral: Exercise, nutritional and pharmaceutical counceling|Behavioral: Nutritional and pharmaceutical counceling
  Outcome Measures:             Functional capacity measured by peak exercise oxygen consumption|Muscle respiratory strength|Body composition (body fat percentage)|Cardiac function (maily ejection fraction)|Laboratorial biomarkers composite|Quality of life|24 hours Holter|Nutritional assessment|Pharmaceutical assessment|Microvascular reactivity|Body mass index
  Sponsor/Collaborators:        Evandro Chagas National Institute of Infectious Disease|National Institute of Cardiology, Laranjeiras, Brazil
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   30
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    CAAE:38038914.6.0000.5262
  Start Date:                   March 2015
  Primary Completion Date:      January 2017
  Completion Date:              January 2017
  First Posted:                 August 7, 2015
  Results First Posted:         
  Last Update Posted:           July 27, 2017
  Locations:                    Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation., Rio de Janeiro, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02517632

Study 58:
  NCT Number:                   NCT02516293
  Title:                        Cardiac Rehabilitation in Chagas Heart Failure
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Chagas Cardiomyopathy
  Interventions:                Behavioral: Exercise, nutritional and pharmaceutical counseling
  Outcome Measures:             Functional Capacity (VO2 max)|Muscle respiratory strength (maximal inspiratory pressure and maximal expiratory pressure)|Body composition (body fat percentage)|Cardiac function (mainly ejection fraction)|Biomarkers (lipid profile and glucose)|Biomarkers (glycated hemoglobin)|Quality of life by Minnesota Living with heart failure questionnaire (MLHFQ)|Anthropometry
  Sponsor/Collaborators:        Evandro Chagas National Institute of Infectious Disease
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 2|Phase 3
  Enrollment:                   12
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CAAE 0055.0.009.000-11
  Start Date:                   May 2013
  Primary Completion Date:      January 2014
  Completion Date:              December 2014
  First Posted:                 August 5, 2015
  Results First Posted:         
  Last Update Posted:           August 5, 2015
  Locations:                    Evandro Chagas National Institute of Infectious Disease, Rio de Janeiro, RJ, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02516293

Study 59:
  NCT Number:                   NCT01006473
  Title:                        Exercise Training in Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Cardiomyopathy|Exercise Training
  Interventions:                Other: Exercise training
  Outcome Measures:             Functional capacity|Functional class|Health related quality of life|BNP levels|Complications related to the exercise training
  Sponsor/Collaborators:        Federal University of Minas Gerais
  Gender:                       All
  Age:                          30 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   37
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CNPq402024/2005-2
  Start Date:                   March 2007
  Primary Completion Date:      March 2008
  Completion Date:              March 2009
  First Posted:                 November 1, 2009
  Results First Posted:         
  Last Update Posted:           August 13, 2015
  Locations:                    Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01006473

Study 60:
  NCT Number:                   NCT01006486
  Title:                        Outcomes of an Anticoagulation Clinic in an University Hospital
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Cardiopathy|Chagas Disease|Hemorrhage|Thrombosis
  Interventions:                Other: Anticoagulation clinic|Other: Standard anticoagulation care
  Outcome Measures:             Time in therapeutic range|Hemorrhagic events|Thromboembolic events
  Sponsor/Collaborators:        Federal University of Minas Gerais
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   280
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Health Services Research
  Other IDs:                    COEP376/09
  Start Date:                   November 2009
  Primary Completion Date:      August 2011
  Completion Date:              August 2011
  First Posted:                 November 1, 2009
  Results First Posted:         
  Last Update Posted:           October 25, 2011
  Locations:                    Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01006486

Study 61:
  NCT Number:                   NCT00023556
  Title:                        Genetic Architecture of Heart Disease in Rural Brazil
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Disease|Heart Diseases|Arrhythmia|Heart Failure, Congestive
  Interventions:                
  Outcome Measures:             
  Sponsor/Collaborators:        National Heart, Lung, and Blood Institute (NHLBI)
  Gender:                       All
  Age:                          18 Years to 100 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   
  Funded Bys:                   NIH
  Study Type:                   Observational
  Study Designs:                
  Other IDs:                    982|R01HL066480-05
  Start Date:                   September 2001
  Primary Completion Date:      August 2008
  Completion Date:              August 2008
  First Posted:                 September 7, 2001
  Results First Posted:         
  Last Update Posted:           July 12, 2016
  Locations:                    
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00023556

Study 62:
  NCT Number:                   NCT01340963
  Title:                        The Signal-averaged ElectrocArdiogram in Long Term Follow-up of Chronic CHagas Disease - RIO de Janeiro Cohort
  Acronym:                      SEARCH-Rio
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Cardiac Arrhythmia|Stroke|Left Ventricular Function Systolic Dysfunction|Cardiac Death
  Interventions:                
  Outcome Measures:             Cardiac death [Time Frame: up to 10 years ]|Ventricular tachycardia|Stroke, either fatal or nonfatal|Persistent atrial fibrillation|Cardiac function and dimensions
  Sponsor/Collaborators:        Universidade Gama Filho|Rio de Janeiro State University|The University of Texas Health Science Center, Houston|Instituto Nacional de Cardiologia de Laranjeiras
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   100
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    012345/96
  Start Date:                   June 1995
  Primary Completion Date:      March 2001
  Completion Date:              December 2012
  First Posted:                 April 25, 2011
  Results First Posted:         
  Last Update Posted:           December 10, 2013
  Locations:                    University of Texas at Houston, Houston, Texas, United States|Hospital Universitário Pedro Ernesto, Rio de Janeiro, RJ, Brazil|Universidade Gama Filho, Rio de Janeiro, RJ, Brazil|Instituto Nacional de Cardiologia, Rio de Janeiro, RJ, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01340963

Study 63:
  NCT Number:                   NCT02544139
  Title:                        Specificity Study of Diagnostic for Chagas Disease
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Infectious Diseases
  Interventions:                Other: Chagas Detect Plus
  Outcome Measures:             number of subjects with negative result
  Sponsor/Collaborators:        InBios International, Inc.
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   200
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only|Time Perspective: Prospective
  Other IDs:                    DSC0227
  Start Date:                   July 2015
  Primary Completion Date:      March 2016
  Completion Date:              March 2016
  First Posted:                 September 9, 2015
  Results First Posted:         
  Last Update Posted:           August 18, 2017
  Locations:                    Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, United States
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02544139

Study 64:
  NCT Number:                   NCT01566617
  Title:                        Impact of the Pharmaceutical Care on the Quality of Life in Patients With Chagas Heart Disease
  Acronym:                      ChagasCare
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Heart Disease
  Interventions:                Other: Standard care and Pharmaceutical care|Other: Standard care
  Outcome Measures:             Quality of life.|Incidence and types of drug-related problems|Physical functional capacity.
  Sponsor/Collaborators:        Evandro Chagas Institute of Clinical Research|Alejandro Marcel Hasslocher Moreno, MD MSc PhD student|Andrea Costa, MD PhD|Andrea Silvestre de Sousa, MD PhD|Luiz Henrique C. Sangenis, MD MSc PhD student|Marcelo Teixeira de Holanda, MD MSc PhD student|Mayara da Costa Chambela - MSc student|Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD|Roberto Magalhães Saraiva, MD PhD|Sergio Salles Xavier, MD PhD
  Gender:                       All
  Age:                          18 Years to 76 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   88
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Care Provider)
  Other IDs:                    Chagas2303|0034.0.009.000-11
  Start Date:                   October 2012
  Primary Completion Date:      January 2017
  Completion Date:              March 2017
  First Posted:                 March 29, 2012
  Results First Posted:         
  Last Update Posted:           January 21, 2016
  Locations:                    Evandro Chagas Clinical Research Institute, Rio de Janeiro, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01566617

Study 65:
  NCT Number:                   NCT03708133
  Title:                        Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet Formulation
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Bioequivalence
  Interventions:                Drug: Nifurtimox (Lampit, BAYA2502)_Test|Drug: Nifurtimox (Lampit, BAYA2502)_Reference
  Outcome Measures:             AUC of nifurtimox in plasma|AUC(0-tlast) of nifurtimox in plasma|Cmax of nifurtimox in plasma|tmax of nifurtimox in plasma|t1/2 of nifurtimox in plasma|AUCnorm of nifurtimox in plasma|Cmax,norm of nifurtimox in plasma|Number of participants with treatment emergent adverse events
  Sponsor/Collaborators:        Bayer
  Gender:                       All
  Age:                          18 Years to 45 Years   (Adult)
  Phases:                       Phase 1
  Enrollment:                   24
  Funded Bys:                   Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Other
  Other IDs:                    19500
  Start Date:                   December 5, 2018
  Primary Completion Date:      April 17, 2019
  Completion Date:              June 18, 2019
  First Posted:                 October 17, 2018
  Results First Posted:         
  Last Update Posted:           June 11, 2020
  Locations:                    FP Clinical Pharma, Buenos Aires, Ciudad Auton. De Buenos Aires, Argentina
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03708133

Study 66:
  NCT Number:                   NCT01681420
  Title:                        Improving Blood Safety and HIV Testing in Brazil
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   HIV|Herpes Simplex 2|Hepatitis C|Hepatitis B|Chagas Disease
  Interventions:                Behavioral: HIV Counseling and Testing|Behavioral: Blood Donation
  Outcome Measures:             HSV-2 Prevalence in Blood Donors|Intervention Impact in Blood Donors|Prevalence of Transfusion-Transmitted Infections in Blood Donors
  Sponsor/Collaborators:        Blood Systems Research Institute
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   11900
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Prevention
  Other IDs:                    10849
  Start Date:                   August 1, 2012
  Primary Completion Date:      May 31, 2013
  Completion Date:              January 31, 2015
  First Posted:                 September 10, 2012
  Results First Posted:         
  Last Update Posted:           January 18, 2018
  Locations:                    Fundação Pró-sangue Hemocentro de São Paulo, Sao Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01681420

Study 67:
  NCT Number:                   NCT03193749
  Title:                        A Trial Testing Amiodarone in Chagas Cardiomiopathy
  Acronym:                      ATTACH
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy
  Interventions:                Drug: Amiodarone Hydrochloride|Drug: Placebo Oral Tablet
  Outcome Measures:             Positive PCR for Trypanosoma cruzi|Composite of clinical events|Elements of the composite outcome of clinical events individually
  Sponsor/Collaborators:        Fundación Cardioinfantil Instituto de Cardiología|Instituto de Corazón de Bucaramanga
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   200
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    880-2015|277872553480
  Start Date:                   June 12, 2017
  Primary Completion Date:      June 2020
  Completion Date:              December 2020
  First Posted:                 June 21, 2017
  Results First Posted:         
  Last Update Posted:           June 21, 2017
  Locations:                    Fundación Cardioinfantil - Instituto de Cardiología, Bogotá, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT03193749

Study 68:
  NCT Number:                   NCT02154269
  Title:                        Evaluation of G-CSF (Colony Stimulating Factor) in Patients With Chronic Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chronic Chagasic Myocarditis
  Interventions:                Drug: Treatment with G-CSF (Granulocyte colony stimulating factor)|Drug: Placebo saline
  Outcome Measures:             NYHA (New York Heart Association) functional class improvement|Assessment of cardiovascular function measured by transthoracic echocardiography|Assessment of cardiovascular function measured by cardiac magnetic resonance imaging|Evaluation of functional capacity assessed by treadmill test and by 6-minute walk test|Evaluation of improvement of quality of life|Determination of tolerability
  Sponsor/Collaborators:        Hospital Sao Rafael
  Gender:                       All
  Age:                          20 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 2
  Enrollment:                   70
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    PCL07/12
  Start Date:                   September 2015
  Primary Completion Date:      October 2019
  Completion Date:              June 2020
  First Posted:                 June 3, 2014
  Results First Posted:         
  Last Update Posted:           August 24, 2020
  Locations:                    Hospital São Rafael, Salvador, Bahia, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02154269

Study 69:
  NCT Number:                   NCT04853758
  Title:                        Angiotensin Receptor-Neprilysin Inhibition in Chagas Cardiomyopathy With Reduced Ejection Fraction: ANSWER-HF.
  Acronym:                      ANSWER-HF
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy
  Interventions:                Drug: Sacubitril / Valsartan Oral Tablet [Entresto]|Drug: Enalapril
  Outcome Measures:             Change of left ventricular ejection fraction (LVEF)|Number of premature ventricular beats|Percentage of premature ventricular beats.|Ventricular arrhythmias density|Sustained ventricular tachycardia rates|New York Heart Association functional class|Ventricular remodeling - left ventricular systolic diameter|Ventricular remodeling - left ventricular diastolic diameter.|Ventricular remodeling - left ventricular systolic volume.|Ventricular remodeling - left ventricular diastolic volume|Ventricular remodeling - thickness of the interventricular septum.|Ventricular remodeling - thickness of the left ventricular posterior wall..|Safety biochemical biomarkers - urea.|Safety biochemical biomarkers - creatinine.|Evaluation of biomarkers - systemic cytokines.|Evaluation of biomarkers - MicroRNA.|Evaluation of biomarkers - NT-proBNP|Safety biochemical biomarkers - potassium.|Safety biochemical biomarkers - sodium.
  Sponsor/Collaborators:        University of Sao Paulo General Hospital|InCor Heart Institute
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   200
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    33360220500000068
  Start Date:                   May 6, 2021
  Primary Completion Date:      March 1, 2023
  Completion Date:              March 1, 2023
  First Posted:                 April 21, 2021
  Results First Posted:         
  Last Update Posted:           May 7, 2021
  Locations:                    Heart Institute (Incor) University of Sao Paulo, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT04853758

Study 70:
  NCT Number:                   NCT01863576
  Title:                        Effects of Omega-3 Supplementation on the Cytokine and Lipid Profiles in Patients With Chronic Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy
  Interventions:                Dietary Supplement: Omega-3|Dietary Supplement: Placebo Comparator
  Outcome Measures:             Cytokine profile|Lipid profile
  Sponsor/Collaborators:        Evandro Chagas Institute of Clinical Research|Andrea Silvestre de Sousa, MD PhD|Alejandro Marcel Hasslocher, MD MSc PhD student|Andrea Pereira de Souza, PhD|Claudia Santos de Aguiar Cardoso, MSc|Patricia Dias de Brito, PhD|Pedro Emmanuel Alvarenga Americano do Brasil, MD PhD|Roberta Olmo Pinheiro, PhD|Roberto Magalhães Saraiva, MD PhD|Sergio Salles Xavier, MD PhD|Paula Simplicio da Silva, MSc PhD student
  Gender:                       All
  Age:                          18 Years to 85 Years   (Adult, Older Adult)
  Phases:                       Early Phase 1
  Enrollment:                   40
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Health Services Research
  Other IDs:                    0037.0.009.000-10
  Start Date:                   March 2013
  Primary Completion Date:      January 2014
  Completion Date:              December 2015
  First Posted:                 May 29, 2013
  Results First Posted:         
  Last Update Posted:           September 9, 2016
  Locations:                    Evandro Chagas Institute of Clinical Research, RJ, Br, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01863576

Study 71:
  NCT Number:                   NCT05519046
  Title:                        Cardiac Contractility Modulation in Chagas Heart Disease
  Acronym:                      FIX-Chagas
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Heart Failure|Systolic Dysfunction|Right Bundle Branch Block and Left Anterior Fascicular Block|Right Bundle Branch Block and Left Posterior Fascicular Block
  Interventions:                Device: Cardiac Contractility Modulation (CCM)|Device: CRT
  Outcome Measures:             QoL Score|GLS|6MWT|NYHAFC|LVEF|Heart Failure Hospitalization (HFH) checklist
  Sponsor/Collaborators:        InCor Heart Institute|Impulse Dynamics|I2medi Comercial Medica LTDA
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   60
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment
  Other IDs:                    57563722.3.0000.0068
  Start Date:                   May 6, 2022
  Primary Completion Date:      December 31, 2023
  Completion Date:              December 31, 2023
  First Posted:                 August 29, 2022
  Results First Posted:         
  Last Update Posted:           August 29, 2022
  Locations:                    InCor - HCFMUSP, São Paulo, Sao Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT05519046

Study 72:
  NCT Number:                   NCT01847378
  Title:                        Feasibility of Contact Force Catheter Mapping and Ablation in Epicardial and Endocardial Ventricular Tachycardias
  Acronym:                      EPICONTAC-VT
  Status:                       Unknown status
  Study Results:                No Results Available
  Conditions:                   Ventricular Tachycardia|Sudden Death|Syncope|Chest Pain
  Interventions:                Procedure: Catheter ablation
  Outcome Measures:             Evaluate the feasibility of mapping and ablating ventricular tachycardias in endocardial and epicardial using a contact force catheter|Evaluate the impedance and voltage threshold for scar in chronic chagasic cardiomyopathy
  Sponsor/Collaborators:        Federal University of São Paulo
  Gender:                       All
  Age:                          18 Years to 80 Years   (Adult, Older Adult)
  Phases:                       
  Enrollment:                   10
  Funded Bys:                   Other
  Study Type:                   Observational
  Study Designs:                Observational Model: Cohort|Time Perspective: Prospective
  Other IDs:                    ISII
  Start Date:                   June 2013
  Primary Completion Date:      May 2015
  Completion Date:              August 2015
  First Posted:                 May 6, 2013
  Results First Posted:         
  Last Update Posted:           October 21, 2014
  Locations:                    Federal University of São Paulo, São Paulo Hospital, São Paulo, Brazil|Federal University of São Paulo, São Paulo, Brazil|Federal University of São Paulo, São Paulo, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01847378

Study 73:
  NCT Number:                   NCT00349271
  Title:                        Cell Therapy in Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Terminated
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy
  Interventions:                Procedure: Stem cell|Drug: Filgrastime (G-CSF)|Drug: Standart therapy
  Outcome Measures:             increase of the ejection fraction of the left ventricle|Death by any cause within 1 year of intervention|Difference in life quality as estimated by Minnesota living with Heart Failure Questionnaire at six months and baseline|Difference in NYHA functional class at six months and baseline|Percent number of patients that reached an absolute increase of 5% in ejection fraction at six and twelve months
  Sponsor/Collaborators:        Ministry of Health, Brazil|Financiadora de Estudos e Projetos
  Gender:                       All
  Age:                          18 Years to 65 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   182
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment
  Other IDs:                    EMRTCC-CHG
  Start Date:                   January 2006
  Primary Completion Date:      December 2010
  Completion Date:              December 2011
  First Posted:                 July 6, 2006
  Results First Posted:         
  Last Update Posted:           March 13, 2017
  Locations:                    INCL - National Institute of Cardiology Laranjeiras, Rio de Janeiro, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00349271

Study 74:
  NCT Number:                   NCT00323973
  Title:                        Chagas Cardiomyopathy Bisoprolol Intervention Study: Charity
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Chronic Heart Failure
  Interventions:                Drug: Bisoprolol
  Outcome Measures:             Hospital admission caused by heart failure.|Major adverse cardiovascular events: stroke, systemic embolism, resuscitated sudden death.|Bradycardia requiring pacemaker implantation.|Clinically significant sustained monomorphic ventricular tachycardia causing syncope: sustained ventricular tachycardia or ventricular fibrillation.|Non-cardiovascular death.|Heart failure worsening or mortality related with CHF.|New AV block.|Need for Implantable cardioverter-defibrillator (ICD), Cardiac resynchronization Therapy (CRT) or Pacemaker therapy (PM).|Perceived quality of life worsening.
  Sponsor/Collaborators:        Fundación Cardiovascular de Colombia
  Gender:                       All
  Age:                          18 Years to 70 Years   (Adult, Older Adult)
  Phases:                       Phase 3
  Enrollment:                   500
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    fcv059
  Start Date:                   July 2003
  Primary Completion Date:      July 2005
  Completion Date:              July 2006
  First Posted:                 May 10, 2006
  Results First Posted:         
  Last Update Posted:           November 24, 2010
  Locations:                    Fundación Cardiovascular de Colombia, Floridablanca, Santander, Colombia
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT00323973

Study 75:
  NCT Number:                   NCT01722942
  Title:                        Amiodarone Against ICD Therapy in Chagas Cardiomyopathy for Primary Prevention of Death
  Acronym:                      CHAGASICS
  Status:                       Recruiting
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Non-sustained Ventricular Tachycardia|At Least 10 Points in Rassi Risk Score for Death
  Interventions:                Procedure: ICD implantation|Drug: amiodarone hydrochloride
  Outcome Measures:             all cause mortality|Cardiac mortality|Sudden cardiac death|Worsening heart failure warranting hospitalization|Need for cardiac stimulation in the ICD arm|Need for pacemaker implantation in the amiodarone therapy arm
  Sponsor/Collaborators:        InCor Heart Institute|Ministry of Health, Brazil|Abbott Medical Devices
  Gender:                       All
  Age:                          18 Years to 75 Years   (Adult, Older Adult)
  Phases:                       Not Applicable
  Enrollment:                   1100
  Funded Bys:                   Other|Industry
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment
  Other IDs:                    CHAGASICS
  Start Date:                   October 6, 2014
  Primary Completion Date:      July 31, 2022
  Completion Date:              July 31, 2022
  First Posted:                 November 7, 2012
  Results First Posted:         
  Last Update Posted:           August 30, 2021
  Locations:                    Hospital Ana Nery, Salvador, BA, Brazil|Hospital Universitário Walter Cantideo, Fortaleza, CE, Brazil|Instituto de Cardiologia do Distrito Federal, Brasilia, DF, Brazil|Anis Rassi Hospital, Goiania, GO, Brazil|Hospital das Clínicas de Goiania, Goiania, GO, Brazil|Santa Casa de Goiania, Goiania, GO, Brazil|Hospital Felício Rocho, Belo Horizonte, MG, Brazil|Hospital das Clínicas Samuel Libânio, Pouso Alegre, MG, Brazil|Hospital Escola da Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil|Hospital Geral Universitário, Cuiabá, Mount, Brazil|Hospital Universitário Procape, Recife, PE, Brazil|Hospital Santa Casa de Misericórdia de Curitiba, Curitiba, PR, Brazil|Hospital das Clínicas da UNICAMP, Campinas, SP, Brazil|Santa Casa de Ribeirão Preto, Ribeirão Preto, SP, Brazil|HC - FMUSP / Ribeirão Preto, Ribeirão Preto, SP, Brazil|Instituto de Moléstias Cardiovasculares, São José do Rio Preto, SP, Brazil|Heart Institute (InCor) - Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil|Beneficiência Portuguesa, São Paulo, SP, Brazil|Escola Paulista de Medicina, São Paulo, SP, Brazil|Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01722942

Study 76:
  NCT Number:                   NCT01557140
  Title:                        A Randomized Trial of Carvedilol in Chronic Chagas Cardiomyopathy
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Chagas Cardiomyopathy|Heart Failure|Dilated Cardiomyopathy
  Interventions:                Drug: RASi plus carvedilol
  Outcome Measures:             Changes in left ventricular ejection fraction|Changes in Framingham score|Changes in quality of life (36-item Short-Form Health Survey)|Changes in New York Heart Association functional class|Changes in cardiothoracic ratio|Changes in echocardiographic diastolic function indices|Changes in brain natriuretic peptide levels|Changes in chemokines|Changes in autoantibodies levels
  Sponsor/Collaborators:        Federal University of Minas Gerais
  Gender:                       All
  Age:                          18 Years and older   (Adult, Older Adult)
  Phases:                       Phase 4
  Enrollment:                   42
  Funded Bys:                   Other
  Study Type:                   Interventional
  Study Designs:                Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment
  Other IDs:                    Carvedilol in Chagas disease
  Start Date:                   May 2003
  Primary Completion Date:      March 2004
  Completion Date:              December 2006
  First Posted:                 March 19, 2012
  Results First Posted:         
  Last Update Posted:           August 13, 2015
  Locations:                    Chagas Disease Outpatient Center of the Federal University of Minas Gerais, Belo Horizonte, Minas Gerais, Brazil
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT01557140

Study 77:
  NCT Number:                   NCT02134548
  Title:                        Sensitivity Study of Diagnostic for Detection of Chagas Infection
  Acronym:                      
  Status:                       Completed
  Study Results:                No Results Available
  Conditions:                   Infectious Diseases
  Interventions:                
  Outcome Measures:             number of subjects with positive result
  Sponsor/Collaborators:        InBios International, Inc.
  Gender:                       All
  Age:                          Child, Adult, Older Adult
  Phases:                       
  Enrollment:                   1601
  Funded Bys:                   Industry
  Study Type:                   Observational
  Study Designs:                Observational Model: Case-Only
  Other IDs:                    DSC0226
  Start Date:                   June 2013
  Primary Completion Date:      September 2015
  Completion Date:              September 2015
  First Posted:                 May 9, 2014
  Results First Posted:         
  Last Update Posted:           December 8, 2015
  Locations:                    Universidad Catolica Boliviana San Pablo, Unidad Academica Santa Cruz, (Cei), Santa Cruz, Bolivia|Laboratorio SANALAB, Santiago, Chile
  Study Documents:              
  URL:                          https://ClinicalTrials.gov/show/NCT02134548

